Impact of fasting during Ramadan in patients with type 2 diabetes mellitus
Abstract
Purpose: Fasting during Ramadan is a religious obligation for Muslims. Extended fasting can create undesirable acute complications of diabetes such as hypoglycemia or hyperglycemia. In this study, we aimed to evaluate the impact of fasting on glucose regulation in diabetic patients who fast during Ramadan.
Materials and Methods: Patients were informed about the possible side effects of fasting for them and those who stated that they will be fasting during Ramadan were called one month after Ramadan. In this retrospective cohort study by telephone interview, the number of fasting days, daily measurements of glucose, the number of acute complications if existed and whether the patients have changed their treatments were asked.
Results: Forty six patients were included in this study. Mean age was 54.3±9.5 yr. The average fasting day was 25.24±2.4. They were categorized according to the risk stratifications. The number of hypoglycemic events was not higher than detected six months prior to the Ramadan. Most of the patients had hyperglycemia rather than hypoglycemia. All of the patients who had hypo-or hyperglycemia did not interrupt their fasting and did not change their medications.
Conclusion: Patients who fasted during Ramadan have a tendency both hypoglycemia and hyperglycemia. To improve glycemic regulation and keep these patients in a safe and acceptable glucose range, Pre-Ramadan education is necessary.
Keywords
Kaynakça
- 1. Fereidoun Azizi. Islamic Fasting and Health. Ann Nutr Metab. 2010;56: 273–282.
- 2. Salti I, Bénard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Voinet C, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306–11.
- 3. Jabbar A, Hassanein M, Beshyah SA, Boye KS, Yu M, Babineaux SM. CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents. Diabetes Res Clin Pract. 2017;132:19-26.
- 4. S. Bajaj. Newer glucose-lowering therapy drugs in Ramadan. Journal of the Pakistan Medical Association. 2015;65(Suppl 5 ):40-43.
- 5. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance. Diabetes and Ramadan:Practical guidelines. Diabetes Res Clin Pract. 2017;126:303-316.
- 6. Ahmedani MY, Haque MS, Basit A, Fawwad A, Alvi SF. Ramadan prospective diabetes study: the role of drug dosage and timing alteration, active glucose monitoring and patient education. Diabet Med. 2012;29(6):709–15.
- 7. Hassanein M, Bravis V, Hui E, Devendra D. Ramadan-focused education and awareness in type 2 diabetes. Diabetologia. 2009;52(2):367–8.
- 8. Patel NR, Kennedy A, Blickem C, Rogers A, Reeves D, Chew-Graham C. Having diabetes and having to fast: a qualitative study of British Muslims with Diabetes. Health Expect. 2015;18:1698-708.
- 9. J aleel MA, Raza SA, Fathima FN, Jaleel BN. Ramadan and diabetes: As- Saum (The fasting). Indian J Endocrinol Metab. 2011;15(4):268–273.
- 10. Pinelli NR, Jaber LA. Practices of Arab American patients with type 2 diabetes mellitus during Ramadan. J Pharm Pract. 2011;24(2):211–215. 11. Cesur M, Corapcıoglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glycemic effects of glimepiride, repaglinide and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract. 2007; 75:141-147.
